Dharmacon and Bayer Pharmaceuticals expand siRNA supply agreement
Dharmacon, the global supplier of innovative RNA and RNA interference (RNAi) research products, is to expand its existing agreement to supply custom siRNA reagents to Bayer Pharmaceuticals Corporation for use in target validation and drug discovery.
Dharmacon, the global supplier of innovative RNA and RNA interference (RNAi) research products, is to expand its existing agreement to supply custom siRNA reagents to Bayer Pharmaceuticals Corporation for use in target validation and drug discovery.
The siRNA reagents are being designed using Dharmacon's proprietary SMARTselection and SMARTpool technologies.
Under the terms of the agreement, during the first quarter of 2004 Dharmacon will supply Bayer with siRNA reagents for approximately 4,000 gene targets for research in several therapeutic areas. The SMARTpool siRNA supplied by Dharmacon will be a major gene-silencing platform used for Bayer's in-house target validation work.
'This new agreement reflects Bayer's ongoing commitment to leadership in applying valuable new technologies like RNAi to our drug discovery research,' said Dr Haren Vasavada, director of molecular biology at the Bayer Research Center in West Haven, Connecticut.